ICAGEN - CORE ASSETS, PARTNERED PROGRAMS AND ION CHANNEL TECHNOLOGIES
Technology Platform. Icagen’s extensive biological capability focused on ion channels, transporters and x-ray fluorescence, along with a strong track record in novel drug discovery from screening to lead optimization. Ion channels are key components in a wide variety of biological processes that involve rapid changes in cells and have broad therapeutic applicability including cancer, metabolic disease, pain, neurological diseases, infectious diseases and others. Roche Collaboration to develop ... and commercialize therapies for neurological diseases. The collaboration provides research funding, potential milestone payments of up to $274 million and tiered royalty payments should a drug be commercialized. Cystic Fibrosis Foundation (CFF) Collaboration to discover therapeutics to treat patients with cystic fibrosis caused by specific genetic mutations. The CFF collaboration allows for up to $11 million in research funding, milestone payments of up to $59 million and tiered royalties on sales, should a product be commercialized. Proprietary Service Unit to Drive New Collaborations and Revenue, including a 32-person R&D team based in Raleigh, N.C., now known as Icagen, a Ligand Company, focused on drug discovery of ion channels and transporters. Icagen provides Ligand with an East Coast operation to efficiently serve partners and brings a portfolio of current or recent/active collaboration agreements with over 30 biopharma companies plus an ongoing business development pipeline. Novel, Unpartnered Programs that include six preclinical-stage assets applicable to a range of therapy areas including diabetes, Parkinson’s disease, pain and other disorders.
ICAGEN - CORE ASSETS, PARTNERED PROGRAMS AND ION CHANNEL TECHNOLOGIES
Industry:
Biopharma Biotechnology
Address:
Durham, North Carolina, United States
Country:
United States
Status:
Active
Similar Organizations
DeepBiome Therapeutics
DeepBiome Therapeutics is an operator of a biotechnology company intended to develop a new drug discovery platform.
More informations about "Icagen - Core Assets, Partnered Programs And ION Channel Technologies"
Icagen - Core Assets, Partnered Programs And ION Channel …
Technology Platform. Icagen’s extensive biological capability focused on ion channels, transporters and x-ray fluorescence, along with a strong track record in novel drug discovery … See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Apr 2, 2020 Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies Download as PDF April 02, 2020 Ligand Pharmaceuticals Incorporated … See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Apr 2, 2020 About Icagen’s Ion Channel Technology and Capability, and Integration with Ligand Technologies Icagen’s medicinal chemistry, in silico and computational chemistry (including … See details»
Ligand agrees to acquire core assets, partnered programmes and …
Feb 12, 2020 Recommended companies Ligand Pharmaceuticals announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’s North Carolina … See details»
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion ...
Feb 11, 2020 Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen Transaction Expected to be Immediately Accretive to Revenues and … See details»
Ligand Buys Icagen’s Core Assets, Partnered Programs …
Feb 12, 2020 Ligand Pharmaceuticals said it is acquiring the core assets of Icagen, a rare disease and neuroscience drug discovery biotech, for $15 million in cash. The deal includes partnered programs, proprietary ion channel … See details»
Ligand Pharmaceuticals will acquire core assets, partnered …
Feb 14, 2020 The acquired assets include Icagen’s proprietary ion channel platforms, partnered programs on neurological diseases and cystic fibrosis, as well as internal programs on … See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Icagen’s extensive biological capability focused on ion channels, transporters and x-ray fluorescence, along with a strong track record in novel drug discovery from screening to lead … See details»
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion ...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.'s North Carolina operations, … See details»
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion ...
Feb 11, 2020 Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen Download as PDF February 11, 2020 Transaction Expected to be … See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Apr 2, 2020 Technology Platform. Icagen’s extensive biological capability focused on ion channels, transporters and x-ray fluorescence, along with a strong track record in novel drug … See details»
Ligand Agrees To Acquire Core Assets, Partnered Programs And …
Feb 11 (Reuters) - Ligand Pharmaceuticals Inc: * LIGAND AGREES TO ACQUIRE CORE ASSETS, PARTNERED PROGRAMS AND ION CHANNEL TECHNOLOGIES FROM ICAGEN … See details»
Ligand to purchase core assets, partnered programmes and ion …
Feb 12, 2020 Icagen Inc's North Carolina operations include partnered programmes, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening … See details»
Icagen - Core Assets, Partnered Programs And ION Channel …
Acquired Organization: Icagen - Core Assets, Partnered Programs And ION Channel Technologies Icagen - applications and x-ray fluorescence assays integrate into and expand … See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Apr 2, 2020 The acquisition of Icagen brings Ligand the following: Technology Platform. Icagen's extensive biological capability focused on ion channels, transporters and x-ray fluorescence, … See details»
Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion ...
Ligand Pharmaceuticals Incorporated announces the signing of an agreement whereby Ligand will acquire the core assets of Icagen, Inc.’ s North Carolina operations, including partnered … See details»
Ligand Completes Acquisition Of Icagen Core Assets, Partnered …
Apr 2, 2020 Ligand Completes Acquisition Of Icagen Core Assets, Partnered Programs And Ion Channel Technologies By Reuters April 2, 20202:06 PM PDTUpdated April 2, 2020 See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen's North Carolina operations. As previously announced, … See details»
Ligand Completes Acquisition of Icagen Core Assets, Partnered …
Proprietary Service Unit to Drive New Collaborations and Revenue, including a 32-person R&D team based in Raleigh, N.C., now known as Icagen, a Ligand Company, focused on drug … See details»
Ligand Completes Acquisition Of Icagen Core Assets, Partnered …
Apr 2, 2020 Ligand Pharmaceuticals Inc: * LIGAND COMPLETES ACQUISITION OF ICAGEN CORE ASSETS, PARTNERED PROGRAMS AND ION CHANNEL TECHNOLOGIES Source … See details»